Book Overview
Bladder Cancer: Diagnosis and Clinical Management (2015) is a comprehensive, multidisciplinary reference authored by leading experts including Seth P. Lerner, Mark P. Schoenberg, Cora N. Sternberg, Bryan T. George, Cohen M. Samuel, Derek Raghavan, Michael Bailey, and Michael Sarosdy. The 448-page volume addresses the full spectrum of bladder cancer care, from pathology and diagnosis through treatment modalities, urinary reconstruction, systemic therapies, and survivorship issues. It is intended primarily for urologists, oncologists, pathologists, radiation oncologists, and allied healthcare professionals involved in bladder cancer management.
The book’s scope encompasses both non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), integrating clinical, pathological, molecular, and surgical perspectives. It emphasizes evidence-based approaches, emerging technologies, and evolving therapeutic strategies, including intravesical therapies, radical and partial cystectomy techniques, urinary diversions, systemic chemotherapy, radiotherapy, and novel molecular diagnostics. The text also highlights patient-centered care, quality of life, healthcare delivery challenges, and the growing role of patient advocacy.
Part I: Diagnosis and Treatment of Non-Muscle-Invasive Bladder Cancer
This section provides a detailed foundation on the pathology, risk stratification, diagnostic tools, and management strategies for NMIBC, which comprises approximately 75% of bladder cancer cases.
Chapter 1: Pathology
Bladder cancer is a heterogeneous disease with diverse histological subtypes and clinical behaviors. The majority are urothelial carcinomas, presenting as superficial papillary or flat lesions, carcinoma in situ (CIS), or invasive tumors. The WHO/ISUP grading system classifies papillary tumors into low-grade and high-grade, with a distinct category for papillary urothelial neoplasm of low malignant potential (PUNLMP). Divergent differentiation (e.g., squamous, glandular) is common, particularly in invasive tumors, and has clinical implications.
Normal urothelium consists of 4-7 cell layers with uniform nuclei, while reactive changes can mimic neoplasia. Immunohistochemistry aids diagnosis but has variability. Flat CIS is a high-grade lesion with marked atypia and loss of polarity, detectable by urine cytology due to cell shedding. Papillary lesions range from benign papillomas to high-grade papillary urothelial carcinoma (HGPUC), with low-grade tumors showing lower progression risk but frequent recurrence. Accurate distinction between lamina propria and muscularis propria invasion is critical for staging and management.
Chapter 2: Risk Stratification of High-Grade Ta, CIS, and T1 Urothelial Carcinoma
Risk stratification guides treatment decisions in NMIBC. High-grade Ta tumors, CIS, and T1 tumors carry variable risks of recurrence and progression. Tools such as the EORTC and CUETO risk tables assist in estimating these risks but have limitations. The European Association of Urology (EAU) categorizes patients into risk groups to tailor therapy.
High-grade Ta tumors require restaging transurethral resection of bladder tumor (TURBT) and BCG induction with maintenance. CIS is uniformly high-risk, treated with BCG, though 40-50% fail therapy, necessitating radical cystectomy (RC). T1 tumors invade the lamina propria and require complete TURBT, repeat resection, and BCG. Prognostic factors include tumor size, multifocality, lymphovascular invasion, and variant histology. Early cystectomy is advised for high-risk features or BCG failure.
Chapter 3: Utility of Urine Biomarkers
Given the high recurrence of bladder cancer and the invasiveness of cystoscopy, urine biomarkers have been investigated to improve surveillance. Six FDA-approved markers (e.g., BTA Stat, NMP22, UroVysion FISH) offer variable sensitivity and specificity but are limited by false positives and cannot replace cystoscopy. Emerging investigational markers include genetic mutations (e.g., FGFR3), DNA methylation panels, microRNAs, and proteomics. While promising, these require further validation before routine clinical use.
Chapter 4: Key Points on Imaging and Detection
White light cystoscopy (WLC) remains the standard diagnostic tool but can miss flat lesions like CIS. Complementary imaging techniques include:
- Photodynamic Diagnosis (PDD): Uses photoactive agents to enhance fluorescence detection, improving sensitivity but with lower specificity and added cost.
- Narrow Band Imaging (NBI): Enhances mucosal vasculature visualization without contrast, improving lesion detection by about 20%.
- Confocal Laser Endomicroscopy (CLE): Provides real-time microscopic imaging akin to histology but is investigational with limited field of view.
- Optical Coherence Tomography (OCT): Offers cross-sectional imaging of bladder wall layers, useful for staging but still investigational.
These adjuncts improve detection and resection completeness, potentially reducing recurrence, though survival benefits remain unproven. False positives are common, especially with inflammation or prior therapy.
Chapter 5: Transurethral Resection of Bladder Tumors (TURBT)
TURBT is the cornerstone of NMIBC treatment. Techniques include monopolar and bipolar loops, with bipolar reducing complications and tissue artifact. Complete tumor resection is essential, with separate specimens for multifocal tumors. Challenges include the obturator reflex causing bladder perforation during lateral wall resections, which can be mitigated by anesthesia and technique adjustments.
Special considerations apply to tumors near ureteral orifices and in bladder diverticula. PDD improves detection and reduces recurrence. Alternative methods such as bipolar plasma vaporization and laser ablation are emerging. Immediate post-TUR chemotherapy with mitomycin-C reduces recurrence but is contraindicated if perforation is suspected. Repeat TURBT is recommended for high-risk lesions to ensure accurate staging and complete resection, improving outcomes. Radical TURBT may be curative in selected muscle-invasive cases but carries progression risk.
Chapter 6: chemotherapy-373-books.html">Intravesical Chemotherapy
Intravesical therapy reduces recurrence and progression in NMIBC. BCG and mitomycin-C (MMC) are primary agents, with doxorubicin and thiotepa less effective. Immediate post-operative single-dose chemotherapy reduces recurrence by approximately 39%, especially in solitary, fully resected tumors. Instillation should occur within 6 hours post-TURBT and be retained for 1-2 hours.
BCG is preferred for high-risk patients; chemotherapy is reserved for BCG-intolerant or refractory cases. Limitations include variable patient response and the need for further research on combination and sequential therapies.
BCG induces a local Th1 immune response, with maintenance therapy improving outcomes. Side effects include cystitis-like symptoms, managed by dose adjustments. BCG failures require aggressive follow-up and often radical cystectomy.
chemotherapy-373-books.html">Intravesical chemotherapy faces challenges such as poor urothelial penetration and rapid clearance; device-assisted methods like hyperthermia, electromotive drug administration (EMDA), and hydrogels enhance delivery and efficacy. Combination and sequential therapies have not conclusively improved outcomes over BCG alone. Thermochemotherapy reduces recurrence and improves bladder preservation but requires further validation.
Chapter 8: High-Grade T1 Bladder Cancer: Diagnosis and Treatment
High-grade T1 bladder cancers (~20% of NMIBC) carry high recurrence and progression risks. Diagnosis requires meticulous TURBT with muscularis propria sampling; absence of muscle in specimens correlates with understaging. Substaging T1 by invasion depth (T1a-c) predicts progression risk.
Follow-up includes frequent cystoscopy and cytology, with upper tract imaging recommended for multifocal tumors. Emerging biomarkers (e.g., p53, karyopherin-α2) are under investigation but not yet clinical. Intravesical BCG reduces recurrence and progression; maintenance therapy is important.
Chapter 9: Management of BCG Failure
BCG failure encompasses refractory, resistant, relapsing, and intolerant disease. Refractory disease, defined by persistent CIS after two BCG courses or early relapse, has poor prognosis; radical cystectomy is the gold standard.
Alternative intravesical therapies include:
- Valrubicin: FDA-approved for BCG-refractory CIS with ~21% complete response.
- Gemcitabine: Effective and well tolerated; complete response rates 39-57%.
- Taxanes (docetaxel, paclitaxel): Promising early results; ongoing trials.
- BCG plus interferon α: Variable success, better in late relapsers.
Early radical cystectomy is recommended for refractory cases; alternative therapies remain investigational.
Chapter 10: Radical Cystectomy Patient Management
Radical cystectomy (RC) complications include infections and bowel issues. Continent diversions are contraindicated in patients with renal/hepatic impairment or inability to self-catheterize. Neoadjuvant cisplatin-based chemotherapy improves survival; renal function assessment is critical. Cardiovascular risk and nutritional status should be evaluated preoperatively. Enhanced recovery pathways reduce hospital stay and improve outcomes.
Intravesical therapies for BCG-refractory NMIBC include paclitaxel conjugates, interferon-alpha combinations, and photodynamic therapy (PDT), showing variable efficacy.
Chapter 11: Radical Cystectomy Techniques and Outcomes
RC with pelvic lymph node dissection (PLND) is the gold standard for high-grade invasive bladder cancer. Clinical understaging is common. Surgical technique and surgeon experience influence outcomes. Female organ-sparing and nerve-sparing approaches may preserve function. Perioperative mortality is 1-3% at centers of excellence, though complications remain high. Enhanced recovery protocols improve outcomes.
Chapter 12: Cystectomy in the Female Patient
Women have higher bladder cancer mortality, possibly due to delayed diagnosis and biological differences. Female-specific surgical considerations include vaginal reconstruction and urethral management. Nerve-sparing approaches may improve continence and sexual function. Orthotopic diversion is feasible based on functional status. Postoperative issues include incontinence and retention; follow-up is tailored to risk.
Chapter 13 and 14: Laparoscopic/Robotic Radical Cystectomy and Clinical Trials
Robot-assisted radical cystectomy (RARC) offers similar operative times, lower blood loss, and comparable complications to open surgery. Oncologic outcomes and continence rates are similar. The learning curve is approximately 20-30 cases. Long-term data are limited, mostly from tertiary centers. Randomized trials show similar surgical margin rates and lymph node yields compared to open surgery. Extended lymphadenectomy is feasible robotically. Long-term survival data for RARC are limited but comparable to open surgery.
Chapter 18: Radical Transurethral Resection (TURBT)
Radical TURBT involves complete, fractionated resection of bladder tumors including exophytic and endophytic components down to the detrusor muscle, with multiple biopsies from tumor beds. Restaging TUR is recommended 2–6 weeks after initial TURBT if radical resection was not performed. Intravesical BCG is indicated for CIS and does not contraindicate bladder preservation.
Radical TURBT may be curative in selected clinically organ-confined muscle-invasive bladder cancer (cT2a), with pT0 rates up to 31%. Clinical understaging occurs in approximately 31% of cases. Prospective studies report progression rates of 17–33%, cancer-specific survival of 81–93%, and bladder preservation rates of 59–75%. Long-term follow-up shows bladder preservation decreases by about 10% over 10 years, while cancer-specific survival remains stable (~79–82%). Complete TURBT and negative muscularis propria biopsies predict better outcomes. TURBT combined with neoadjuvant cisplatin-based chemotherapy improves survival and bladder preservation. Lifelong surveillance with cystoscopy and imaging is mandatory.
Chapter 19: Partial Cystectomy
Partial cystectomy is a less morbid alternative to radical cystectomy for highly selected muscle-invasive bladder cancer patients with small (<4 cm), solitary tumors located in the mobile bladder dome, negative random biopsies, and normal bladder capacity. It is preferred for tumors in bladder diverticula and urachal adenocarcinomas. Complete resection including the urachus and umbilicus is critical to reduce relapse risk.
Combining partial cystectomy with chemotherapy or radiotherapy may improve outcomes. Surgical technique emphasizes full bladder mobilization, tumor isolation to prevent spillage, negative margins confirmed by frozen sections, and bilateral pelvic lymphadenectomy. Minimally invasive approaches are feasible but lack long-term data. Bladder recurrence occurs in 29–78%, mostly non-invasive and treatable endoscopically. Five-year overall survival ranges from 40–80%, comparable to radical cystectomy in selected patients. Salvage cystectomy after recurrence is effective. Partial cystectomy preserves bladder and sexual function with less morbidity.
Chapter 20: Integrating Chemotherapy and Radiotherapy for Bladder Cancer
Trimodality bladder-preservation therapy combines maximal TURBT, chemotherapy, and radiation for patients unsuitable for or motivated to avoid radical cystectomy. This approach is safe and effective, with good bladder function and acceptable toxicity.
Treatment involves maximal TURBT, induction chemoradiation (~40 Gy), cystoscopic assessment, and consolidative chemoradiation (~65 Gy) for complete responders; incomplete responders undergo salvage cystectomy. Concurrent chemotherapy agents (cisplatin, mitomycin-C/5-FU, gemcitabine, paclitaxel) enhance radiosensitivity; cisplatin is standard but alternatives exist for renal impairment.
The BC2001 trial demonstrated improved loco-regional control and survival with mitomycin-C/5-FU plus radiation versus radiation alone. Neoadjuvant chemotherapy improves survival mainly by reducing distant metastases; its benefit in bladder preservation is under investigation. Local recurrence occurs in 24–43%, with 11–18.5% muscle-invasive; salvage cystectomy is effective. Five-year overall survival ranges 48–65%. Bladder preservation offers quality-of-life advantages, especially in elderly or infirm patients.
Chapter 21: Key Points on Bladder-Sparing Therapy
Bladder-sparing therapy and radical cystectomy have comparable long-term survival, though patient selection and staging differ. Clinical understaging is common. Bladder-sparing approaches benefit older or less fit patients. Standard NMIBC treatment is TUR plus intravesical BCG; about half develop BCG-refractory disease requiring cystectomy. Combined chemoradiation may be effective for high-risk NMIBC patients unfit for surgery. Biomarkers like MRE11 may predict chemoradiation outcomes. Trimodality therapy offers durable control with preserved bladder function and acceptable toxicity.
Part IV: Urinary Tract Reconstruction
This part addresses surgical techniques and outcomes related to urinary diversion following radical cystectomy, focusing on orthotopic neobladders, continent cutaneous diversions, and non-continent urinary diversions.
Chapter 21: Orthotopic Neobladder
After radical cystectomy, urinary diversion is necessary. The ileal conduit is the standard but has drawbacks related to body image and stoma care. Orthotopic neobladder, a continent diversion using detubularized bowel segments, is an accepted alternative used in approximately 10% of US cystectomy patients.
Eligibility requires normal renal function (eGFR ≥40 mL/min), negative urethral margin, and ability to self-catheterize. Contraindications include prior high-dose pelvic radiation and urethral stricture. Surgical techniques include Studer, Hautmann, and T-pouch configurations. Anti-reflux mechanisms may increase uretero-ileal strictures without clear benefit.
Perioperative complications include urinary leaks and infections. Long-term, 80–90% of patients achieve daytime continence by one year, with nighttime continence recovering more slowly. Urinary retention requiring catheterization is more common in women. Late complications include uretero-ileal strictures (3–6%), pouch stones, and rare secondary malignancies. Orthotopic neobladder offers good functional and oncologic outcomes when no contraindications exist.
Chapter 22: Continent Cutaneous Diversion
Indicated after radical cystectomy when orthotopic substitution is not possible (e.g., positive urethral margins, incontinence). Patient motivation and manual dexterity for clean intermittent self-catheterization are critical; patients over 75 or with neurological deficits often better served by incontinent diversion.
Preoperative evaluation includes renal function and bowel imaging. Pouches are constructed by detubularization and reconfiguration of ileum, colon, or ileocecal segments with continence mechanisms such as appendiceal tunneling or intussusception nipples. Stoma placement at the umbilicus is preferred. Ureteral implantation uses anti-reflux or refluxing techniques depending on reservoir type.
Early complications include metabolic acidosis (~60%) managed with alkali supplementation. Continence rates of approximately 93% are reported. Long-term follow-up includes pouchoscopy and vitamin B12 monitoring. Continent cutaneous diversion is safe and feasible with careful patient selection and surgical expertise.
Chapter 23: Non-Continent Urinary Diversion
The most common diversion after radical cystectomy, especially in elderly or advanced disease patients, is the ileal conduit, considered the gold standard. Transverse colon conduit is preferred after pelvic irradiation. Advantages include simplicity, shorter operative time, and fewer complications. Cutaneous ureterostomy is rarely used, mainly for palliation.
Complications include metabolic acidosis, stomal stenosis, ureterointestinal strictures, parastomal hernia, and upper tract deterioration. Quality of life is generally acceptable, with high patient satisfaction. Follow-up includes renal function monitoring, imaging, and vitamin B12 assessment. Non-continent diversions remain important for elderly or comorbid patients, offering reasonable quality of life and low complication rates.
Systemic Therapy and Molecular Insights
Chapter 24: Molecular Determinants of Chemotherapy Response
Urothelial cancer is chemosensitive; cisplatin-based chemotherapy improves survival but is underutilized due to modest benefit and toxicity. Predictive biomarkers are needed to optimize patient selection. Low expression of DNA repair enzymes BRCA1 and ERCC1 correlates with better response and survival. Low MDR1 drug efflux protein expression also predicts improved outcomes. p53 status shows inconsistent predictive value.
Germline pharmacogenomics and genome-wide association studies are emerging to identify variants influencing response and toxicity. Gene expression models (GEM), such as COXEN, predict chemotherapy sensitivity based on tumor profiles and have shown promise in independent cohorts. Prospective trials like SWOG 1314 are validating GEMs. Personalized chemotherapy selection aims to maximize benefit and minimize harm.
Chapter 26: Adjuvant Chemotherapy for Invasive Bladder Cancer
Adjuvant chemotherapy after radical cystectomy targets micro-metastatic disease. Pathological staging (T3, T4, N+) guides patient selection. Clinical trials show mixed results due to limitations, but meta-analyses support a modest survival benefit with cisplatin-based regimens. Neoadjuvant chemotherapy remains preferred due to better tolerance and response assessment. Adjuvant chemotherapy is reasonable for patients who did not receive neoadjuvant therapy and are cisplatin-eligible. Clinical guidelines recommend neoadjuvant chemotherapy plus cystectomy as standard care. Ongoing research aims to optimize perioperative systemic therapy.
Chapter 27: Treatment of Metastatic Bladder Cancer
First-line treatment is cisplatin-based combination chemotherapy (MVAC or gemcitabine-cisplatin). MVAC has higher toxicity; gemcitabine-cisplatin offers similar efficacy with better safety. Dose-dense MVAC improves response rates but not overall survival. Alternative regimens (PCG, sequential therapies) show promise but with toxicity. Carboplatin-based regimens are less effective, reserved for cisplatin-ineligible patients.
Prognostic factors include performance status, visceral metastases, hemoglobin, and metastatic sites. Molecular biomarkers (ERCC1, BRCA1) predict response. Second-line therapies lack FDA approval; agents like pemetrexed, taxanes, and vinflunine (EMA-approved) show modest activity. Targeted agents (anti-angiogenics, EGFR/HER2 inhibitors, MET inhibitors, epigenetic drugs, immunotherapies) have limited efficacy; ongoing trials explore biomarker-driven approaches. Molecular profiling identifies actionable targets in approximately 69% of tumors. Clinical trial participation is encouraged.
Chapter 28: Treatment of Poor Risk Patients
Advanced urothelial cancer patients have heterogeneous outcomes. Poor risk is defined by Karnofsky Performance Status <80% and presence of visceral metastases, predicting worse survival. Cisplatin-based chemotherapy is standard but many patients are ineligible due to comorbidities. Carboplatin-based regimens yield inferior outcomes. Prognostic nomograms improve individualized survival estimates. Molecular profiling may refine prognostication. Treatment for poor risk and cisplatin-ineligible patients remains challenging and under investigation.
Chapter 29: Molecular Events in Muscle-Invasive Bladder Cancer Development
MIBC harbors frequent somatic mutations and copy number alterations. Key mutated genes include TP53, KDM6A, ARID1A, MLL2, PIK3CA, ERBB3, FGFR3, RB1, and others. Common copy number alterations affect CDKN2A, RB1, EGFR, ERBB2, FGFR3, and MYC. Altered pathways include p53/Rb cell cycle (93%), RTK/RAS/PI3K (72%), and chromatin regulation (89%). ERBB family and FGFR3 mutations/amplifications are potential therapeutic targets. PI3K pathway alterations are common, suggesting opportunities for targeted therapies.
Health-Related Quality of Life and Survivorship
Treatment of bladder cancer, especially MIBC, profoundly affects urinary, sexual, bowel, reproductive functions, and body image. Postoperative complications are common, with significant readmission and mortality rates. Various HRQOL assessment tools exist, including generic instruments (SF-36, EORTC QLQ-C30, FACT-G) and bladder cancer-specific measures (EORTC QLQ-BLM30, FACT-BL, Bladder Cancer Index).
NMIBC patients generally report better HRQOL with bladder-sparing treatments than cystectomy patients. Urinary diversion types impact HRQOL differently: incontinent diversions cause body image and social issues; continent cutaneous diversions require catheterization and may disrupt sleep; orthotopic neobladders preserve body image but may cause nighttime incontinence. Elderly patients are less likely to receive radical cystectomy or continent diversions and report lower satisfaction with neobladders. Women present with more advanced disease, worse survival, and experience diagnostic delays; post-cystectomy, women report worse urinary incontinence and sexual dysfunction than men.
HRQOL studies often have methodological limitations, including cross-sectional designs, small cohorts, and lack of sensitivity to gender- and age-specific issues. Many tools do not capture patients’ supportive care needs or desire for professional help. Improving survivorship requires system-level interventions (survivorship care plans, multidisciplinary teams, improved communication) and patient-level interventions (tailored education, health promotion, navigation services). The Institute of Medicine (IOM) and American Society for Clinical Oncology (ASCO) recommend survivorship care plans; the Bladder Cancer Advocacy Network (BCAN) developed a bladder cancer-specific plan with good acceptability.
Patient navigation programs help overcome barriers to care, improve surveillance compliance, and address psychosocial needs. Electronic health records and mobile technologies offer opportunities to enhance patient-provider communication and surveillance adherence. Informational and supportive care needs include prognosis, rehabilitation, surveillance, body image, sexuality, urinary incontinence, stoma care, and psychosocial support. Despite recommendations, many institutions have yet to implement routine distress screening and survivorship care plans. Future research should focus on longitudinal HRQOL studies, gender- and age-specific outcomes, and randomized trials evaluating survivorship interventions.
Healthcare Delivery and Patient Advocacy
Bladder cancer care faces challenges of both overuse and underuse of interventions. Radical cystectomy is underutilized in Medicare patients with MIBC, while chemotherapy-373-books.html">intravesical chemotherapy post-TURBT is rarely administered despite proven efficacy. Many low-risk patients receive high-intensity treatments without survival benefit, increasing costs and complications.
Regionalization efforts aim to concentrate complex care but may limit access or cause delays. Pay-for-performance initiatives lack bladder cancer-specific measures, limiting quality improvement. Development of bladder cancer-specific quality metrics is needed, with organizations like the American Urological Association (AUA) and Physician Consortium for Performance Improvement (PCPI) playing key roles. Bundled payments and Accountable Care Organizations (ACOs) incentivize efficiency and quality. Urological quality collaboratives demonstrate potential to reduce overuse and improve care via provider feedback and data transparency.
Patient advocacy organizations have emerged as vital partners in advancing bladder cancer care, research, and clinical trials. Key groups include the Bladder Cancer Advocacy Network (BCAN), Bladder Cancer Canada, Action on Bladder Cancer (UK), and the American Bladder Cancer Society. These organizations provide education, support, clinical trial information, and influence research funding priorities. They foster collaboration among patients, clinicians, and researchers, enhancing trial design, accrual, and survivorship care.
Advocacy efforts have increased bladder cancer’s public profile, with inclusion in major research initiatives like The Cancer Genome Atlas and the NCI’s Genitourinary Steering Committee. Patient advocates participate in cooperative group trial design and implementation, ensuring patient-centered research. Continued growth in advocacy and quality initiatives promises to improve outcomes and quality of life for bladder cancer patients.
Summary
This authoritative volume offers an in-depth, multidisciplinary exploration of bladder cancer diagnosis, treatment, reconstruction, systemic therapy, and survivorship. It integrates traditional clinical approaches with cutting-edge molecular insights and emphasizes patient-centered care. The text underscores the complexity of bladder cancer management, highlighting the importance of accurate pathology, risk stratification, and tailored therapies ranging from intravesical treatments to radical surgery and systemic chemotherapy.
Innovations in imaging, urinary biomarkers, and minimally invasive surgical techniques are presented alongside practical guidance on managing complications and optimizing quality of life. The inclusion of health-related quality of life, healthcare delivery challenges, and patient advocacy reflects a holistic approach to bladder cancer care. This resource is valuable for clinicians seeking comprehensive, evidence-based information to guide management decisions and improve patient outcomes in bladder cancer.
